Bondini Silvia, Kallman Jillian, Dan Amy, Younoszai Zahra, Ramsey Lolita, Nader Fatema, Younossi Zobair M
Center for Liver Diseases, Inova Fairfax Hospital, Fairfax, VA, USA.
Liver Int. 2007 Oct;27(8):1119-25. doi: 10.1111/j.1478-3231.2007.01558.x.
Although chronic hepatitis C (CH-C) has consistently been shown to impair patients' health-related quality of life (HRQL), the impact of chronic hepatitis B (CH-B) on HRQL has not been fully explored.
Compare HRQL between patients with CH-B, CH-C, primary biliary cirrhosis (PBC) and healthy controls.
Three HRQL questionnaires [Chronic Liver Disease Questionnaire (CLDQ), Short Form 36 (SF-36) and the Health Utility Index (HUI Mark-2 and Mark-3)] were administered prospectively. Additional clinical and laboratory data and normative data for healthy individuals, were available.
Scores were compared using analysis of variance and multiple regression.
One hundred and forty-six patients with CH-B, CH-C and PBC were included [mean age 47.1 years (+/-11.6), 41% female, 33% cirrhosis]. CH-C and PBC patients scored the lowest on all CLDQ, SF-36 and HUI domains compared with CH-B patients and healthy controls. CH-B patients had scores similar to the healthy population, measured by most CLDQ and SF-36 scales. However, the HUI scores for CH-B patients showed more impairment than population norms. Having CH-B and not having cirrhosis were predictive of utility and HRQL scores in multivariate models.
CH-B patients have better HRQL than CH-C, PBC and population norms. CH-B patients' overall utility scores are lower than population norms.
尽管慢性丙型肝炎（CH-C）一直被证明会损害患者的健康相关生活质量（HRQL），但慢性乙型肝炎（CH-B）对HRQL的影响尚未得到充分研究。
比较CH-B、CH-C、原发性胆汁性肝硬化（PBC）患者与健康对照者的HRQL。
前瞻性地使用了三种HRQL问卷[慢性肝病问卷（CLDQ）、简短健康调查量表36（SF-36）和健康效用指数（HUI Mark-2和Mark-3）]。还可获得额外的临床和实验室数据以及健康个体的规范数据。
使用方差分析和多元回归比较得分。
纳入了146例CH-B、CH-C和PBC患者[平均年龄47.1岁（±11.6），41%为女性，33%有肝硬化]。与CH-B患者和健康对照者相比，CH-C和PBC患者在所有CLDQ、SF-36和HUI领域的得分最低。通过大多数CLDQ和SF-36量表测量，CH-B患者的得分与健康人群相似。然而，CH-B患者的HUI得分显示出比人群规范更多的损害。在多变量模型中，患有CH-B且无肝硬化可预测效用和HRQL得分。
CH-B患者的HRQL优于CH-C、PBC患者及人群规范。CH-B患者的总体效用得分低于人群规范。
